Contrarian sell signals in stocks

Which stocks are flashing contrarian sell signals?

{"response_type": "market_analysis", "acknowledgement": "I've retrieved the top stocks with the highest Z-score, indicating potential contrarian sell signals.", "answer": "**Here are some stocks flashing contrarian signals, with high Z-scores (around +9):**\n\n- **NETEASE INC (NTES)** \u2014 Communication Services, large cap, AAA credit, Z-score 9, rank 160\n- **PALANTIR TECHNOLOGIES INC (PLTR)** \u2014 Technology, mega cap, AAA, Z-score 9, rank 144\n- **COPART INC (CPRT)** \u2014 Industrials, large cap, AAA, Z-score 9, rank 181\n- **FRANCO NEVADA CORP (FNV)** \u2014 Basic Materials, large cap, AAA, Z-score 9, rank 226\n- **UNITED THERAPEUTICS CORP (UTHR)** \u2014 Healthcare, large cap, AAA, Z-score 9, rank 168\n- **ENLIVEX LTD (ENLV)** \u2014 Healthcare, micro cap, BBB, Z-score 9, rank 122\n- **REDDIT INC (RDDT)** \u2014 Communication Services, large cap, AAA, Z-score 9, rank 123\n\nHigh positive Z-scores like these suggest the stocks are potentially undervalued from a contrarian standpoint, signaling they might be ripe for more downside or are outliers in terms of risk-reward. It\u2019s worth exploring whether these stocks have fundamentals or technical setups that justify this signal, but they remain notable contrarian candidates.\n\nWould you like to deep dive into any of these stocks' fundamentals or recent news?", "interpretation": "These stocks show extreme Z-scores, which could indicate they're temporarily out of favor or mispriced, making them potential contrarian sell signals. The risks include further decline if the fundamentals deteriorate or negative news, so it\u2019s crucial to analyze each case individually. Opportunities may exist if the market has overreacted or if technical risk levels are evident.", "hypothesis": {"text": "High Z-scores may represent stocks that are temporarily depressed or out of favor, suggesting potential for mean reversion or continued downside if broader risks materialize.", "confidence": "Moderate"}, "insights": ["Several stocks with Z-scores around +9 also have high market caps, indicating broad market mispricing could be at play.", "Contrarian signals are strongest when combined with deteriorating fundamentals or negative news, which should be checked."], "suggested_questions": ["Check fundamental health of NTES", "View recent news for PLTR", "Compare UTHR and ENLV earnings", "View ENLV page for more analysis"], "charts": [{"type": "bar", "title": "Top 10 Stocks by Z-Score (Contrarian Sell Signals)", "data": [{"label": "NTES", "value": 9.0}, {"label": "PLTR", "value": 9.0}, {"label": "CPRT", "value": 9.0}, {"label": "FNV", "value": 9.0}, {"label": "UTHR", "value": 9.0}, {"label": "ENLV", "value": 9.0}, {"label": "RDDT", "value": 9.0}]}], "actions": [], "supporting_data": [{"label": "Rank: NTES", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: PLTR", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: CPRT", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: FNV", "value": "zscore=9.0", "source": "metrics"}, {"label": "Rank: UTHR", "value": "zscore=9.0", "source": "metrics"}], "risk_watch": "Visit the ticker pages (CPRT, ENLV, FNV) for full credit ratings, financial scores, and fundamental analysis.", "structured_data": null}

Compare UTHR and ENLV earnings

{"response_type": "stock_research", "acknowledgement": "Here's a comparison of the earnings and financial metrics for UTHR and ENLV.", "answer": "**United Therapeutics Corporation (UTHR):**\n- Market Cap: $22.0B, Revenue: $3.15B, Net Income: $1.31B\n- EPS: $27.92, Trailing P/E: 18.38, Forward P/E: 17.08, PEG Ratio: 2.22\n- Price to Book: 3.42, Price to Sales: 6.98, EV/EBITDA: 12.93\n- Sector: Healthcare (Specialty & Generic Drug Makers)\n- EPS and earnings metrics indicate consistent profitability and a moderate valuation for a biopharma.\n\n**Enlivex Ltd. (ENLV):**\n- Market Cap: $25.7M, No reported revenue, Net Income: $1.24B (likely non-operating)\n- EPS: 382.2, Trailing P/E: 0.0038, Forward P/E: -1.88\n- Price to Book: 0.012, EV/EBITDA: -1.24\n- Sector: Healthcare (Biotechnology)\n- Financials show no revenue and negative valuation multiples, reflecting early-stage biotech status and possible non-recurring income.\n\n**Peers:** Both belong to biotechnology-related sectors but differ vastly in scale and maturity. UTHR has larger, stable earnings, while ENLV is a microcap with volatile financials.\n\nThis contrast highlights UTHR as a fundamentally established specialty drug maker versus ENLV\u2019s speculative biotech profile with non-standard earnings.", "interpretation": "UTHR\u2019s earnings and valuation suggest a mature biotech firm with ongoing profitability and reasonable valuation multiples, whereas ENLV\u2019s absence of revenue and odd financial ratios reflect typical early-stage biotech risk and potential volatility. The disparity indicates that ENLV\u2019s contrarian signal may relate to microcap risk and uncertain fundamentals, while UTHR\u2019s signals likely involve market sentiment or technical factors rather than fundamental distress.", "hypothesis": {"text": "The extreme valuation ratios for ENLV may signal speculative positioning or accounting/one-off factors, while UTHR\u2019s healthier fundamentals suggest its contrarian signals stem from price behavior rather than earnings weakness.", "confidence": "High"}, "insights": ["UTHR is a large-cap, profitable biotech with positive earnings momentum.", "ENLV has no reported revenue and atypical valuation ratios, typical of microcap biotech firms."], "suggested_questions": ["Search recent earnings guidance for UTHR", "Analyze valuation multiples for ENLV peers", "Check recent news impacting UTHR or ENLV"], "charts": [{"type": "bar", "title": "Market Capitalization Comparison ($USD)", "data": [{"label": "UTHR", "value": 22008072192.0}, {"label": "ENLV", "value": 25703630.0}]}, {"type": "bar", "title": "Trailing P/E Ratio Comparison", "data": [{"label": "UTHR", "value": 18.38}, {"label": "ENLV", "value": 0.0038}]}, {"type": "bar", "title": "Price to Book Ratio Comparison", "data": [{"label": "UTHR", "value": 3.42}, {"label": "ENLV", "value": 0.012}]}], "actions": [{"label": "Search latest on UTHR earnings", "action_type": "web_search", "parameters": {"query": "UTHR earnings 2026"}}, {"label": "Deep dive into ENLV fundamentals", "action_type": "analyze_stock", "parameters": {"ticker": "ENLV"}}], "supporting_data": [], "risk_watch": "", "structured_data": {"template": "stock_analysis", "stocks": [{"ticker": "UTHR", "name": "United Therapeutics Corporation", "sector": "Healthcare", "market_cap": 22008072192, "pe_trailing": 18.378223, "pe_forward": 17.084682, "pb_ratio": 3.4214616, "dividend_yield": null, "beta": 0.564, "fifty_two_week_high": 609.35, "fifty_two_week_low": 302.19, "peg_ratio": 2.22, "ev_to_ebitda": 12.93}, {"ticker": "ENLV", "name": "Enlivex Ltd.", "sector": "Healthcare", "market_cap": 25703630, "pe_trailing": 0.0038461538, "pe_forward": -1.8846155, "pb_ratio": 0.01202277, "dividend_yield": null, "beta": 1.465, "fifty_two_week_high": 27.15, "fifty_two_week_low": 1.39, "peg_ratio": null, "ev_to_ebitda": -1.237}]}}